Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Cardiology · Heart Failure

Your Subtype, Stage, and Ejection Fraction

At a Glance

Heart failure is described by ejection fraction, ACC/AHA stage, and NYHA functional class. EF shows how the heart pumps, stage reflects disease progression, and NYHA class reflects activity limits; an improved EF usually means remission, not a permanent cure.

When you are diagnosed with heart failure, your doctors will use several classification systems to describe exactly how your heart is working. These labels are not just “medical jargon”—they help your care team determine the most effective treatment for your specific situation.

Understanding Ejection Fraction (EF)

As mentioned in the diagnosis page, your medical team uses imaging like an echocardiogram to measure how well your heart pumps blood [1]. One important measure from this test is your Ejection Fraction (EF).

Think of your heart’s left ventricle as a glass of water. When the heart beats, it doesn’t empty completely. The EF is the percentage of blood that is pumped out of the ventricle with each contraction [2]. A normal EF typically ranges from roughly 55% to 70%. In heart failure, this number helps doctors categorize your condition into different subtypes [2][3]:

  • HFrEF (Heart Failure with Reduced EF): Your EF is 40% or less. This means the heart muscle has weakened and cannot pump with enough force [2].
  • HFmrEF (Heart Failure with Mildly Reduced EF): Your EF is between 41% and 49%. This is considered a middle ground where the heart’s pumping ability is slightly impaired [3].
  • HFpEF (Heart Failure with Preserved EF): Your EF is 50% or higher. An EF in this range does not automatically mean you have HFpEF; the diagnosis requires matching symptoms alongside evidence of high filling pressures or congestion, indicating the heart is too stiff to fill properly [4][2].
  • HFimpEF (Heart Failure with Improved EF): This describes a trajectory where a person previously had an EF of 40% or less, but after treatment, their EF improved to above 40% [2][5].

The “Remission” Concept: Why HFimpEF is Not a Permanent Cure

If your EF improves significantly, it is a major victory and a sign that your treatment is working. However, medical guidelines are very clear: improved EF reflects a state of remission or recovery, not a permanent cure [2][6].

The underlying vulnerabilities of the heart remain. Research shows that stopping medications can lead to a severe relapse. In one small study of patients who recovered from a specific type of dilated cardiomyopathy (the TRED-HF trial), roughly 40% relapsed within six months of stopping their medications [7]. Because of this risk, doctors generally recommend staying on your guideline-directed heart failure therapies indefinitely [8][9]. Always consult your doctor before making any medication changes.

Two Ways of Measuring Your Progress

Doctors use two different “staging” systems to track your heart failure. One looks at the physical progression of the disease, while the other looks at how you feel and function in daily life.

1. ACC/AHA Stages (The Structural Path)

This system (Stages A through D) tracks the progression of the disease itself. It helps doctors understand your medical history and the structural changes in your heart [10].

  • Stage A: You are at high risk for heart failure (e.g., you have high blood pressure or diabetes) but have no structural heart issues and no symptoms [10].
  • Stage B: You have structural heart disease (like a low EF or a thickened heart wall) but have never felt symptoms of heart failure [10].
  • Stage C: You have structural heart disease and either currently have symptoms or have had them in the past [10]. Most people diagnosed with heart failure are in Stage C.
  • Stage D: You have advanced heart failure that causes severe symptoms despite optimal treatments, and may require specialized interventions [10].

2. NYHA Functional Class (The Symptom Scale)

Unlike the stages above, your New York Heart Association (NYHA) Class can improve as treatment takes effect. This scale measures how much your symptoms limit your physical activity [11]. Your clinician will assign this class based on your usual routines and other health conditions.

NYHA Class What it Feels Like
Class I No limitation. Ordinary physical activity (like walking or climbing stairs) does not cause fatigue or breathlessness [11].
Class II Mild limitation. You are comfortable at rest, but ordinary physical activity results in some fatigue or shortness of breath [11].
Class III Marked limitation. You are comfortable at rest, but less-than-ordinary physical activity (such as walking short distances) causes symptoms [11].
Class IV Severe limitation. You are unable to carry out any physical activity without discomfort, and you may feel symptoms even while resting [11].

By understanding both your stage and your class, you can better monitor your health. Your Stage tells you where you are in the overall journey of the disease, while your Class reflects how well your current treatment is helping you live your life [9][11].

Common questions in this guide

What does ejection fraction mean in heart failure?
Ejection fraction (EF) is the percentage of blood the left ventricle pumps out each time it contracts. A typical normal EF is about 55% to 70%, but clinicians interpret it alongside symptoms and other test results.
Which heart failure subtype matches my EF?
HFrEF is an EF of 40% or less, HFmrEF is 41% to 49%, and HFpEF is 50% or higher when symptoms and evidence of high filling pressures or congestion are also present. HFimpEF describes a previous EF of 40% or less that improves above 40% after treatment. Your clinician uses the full clinical picture, not EF alone, to classify your condition.
Does an improved EF mean my heart failure is cured?
Not necessarily. An improved EF generally means remission or recovery rather than a permanent cure, because underlying vulnerabilities can remain. Do not stop or change heart failure medication without speaking with your clinician; treatment is often continued long term.
How is an ACC/AHA stage different from an NYHA class?
ACC/AHA stages A through D describe structural heart disease and its overall progression, from risk to advanced heart failure. NYHA classes I through IV describe how symptoms limit ordinary physical activity, and the class can improve when treatment helps. The stage and class measure different parts of heart failure.
What do ACC/AHA stages A through D mean?
Stage A means high risk but no structural heart disease or symptoms; Stage B means structural heart disease without symptoms; and Stage C means structural heart disease with current or past symptoms. Stage D is advanced heart failure with severe symptoms despite optimal treatment and may require specialized interventions.
What do NYHA Classes I through IV describe?
Class I means ordinary activity causes no symptoms. Class II means mild limitation with ordinary activity, Class III means marked limitation with less-than-ordinary activity, and Class IV means symptoms with any physical activity or even at rest. The class can improve as treatment helps.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my most recent echocardiogram, what is my exact ejection fraction (EF) percentage, and which subtype of heart failure do I have?
  2. 2.Since my EF has improved, am I now classified as having 'Heart Failure with Improved Ejection Fraction' (HFimpEF), and how does that change my long-term outlook?
  3. 3.Can you explain why I need to stay on my heart medications even if my EF has returned to a 'normal' range and I feel much better?
  4. 4.What is my current NYHA functional class, and what specific goals should we set to help me move to a more comfortable class?
  5. 5.Which ACC/AHA stage am I in, and what steps can we take to prevent me from progressing to the next stage?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.

    Baptista R, Rodrigues AM, Bernardo F, et al.

    European heart journal 2026; doi:10.1093/eurheartj/ehag030.

    PMID: 41641552
  2. 2

    Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.

    Bozkurt B, Coats AJS, Tsutsui H, et al.

    European journal of heart failure 2021; (23(3)):352-380 doi:10.1002/ejhf.2115.

    PMID: 33605000
  3. 3

    Heart failure with mildly reduced ejection fraction: emerging frontiers in clinical characteristics, prognosis, and treatment.

    Shang Z, Wang X, Gao W

    Reviews in cardiovascular medicine 2022; (23(1)):30 doi:10.31083/j.rcm2301030.

    PMID: 35092222
  4. 4

    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

    Solomon SD, de Boer RA, DeMets D, et al.

    European journal of heart failure 2021; (23(7)):1217-1225 doi:10.1002/ejhf.2249.

    PMID: 34051124
  5. 5

    Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.

    Savarese G, Vedin O, D'Amario D, et al.

    JACC. Heart failure 2019; (7(4)):306-317 doi:10.1016/j.jchf.2018.11.019.

    PMID: 30852236
  6. 6

    Heart Failure With Improved Ejection Fraction: Is it Possible to Escape One's Past?

    Gulati G, Udelson JE

    JACC. Heart failure 2018; (6(9)):725-733 doi:10.1016/j.jchf.2018.05.004.

    PMID: 30098965
  7. 7

    Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission.

    Cheng L, Hammersley D, Ragavan A, et al.

    European journal of heart failure 2025; (27(1)):113-123 doi:10.1002/ejhf.3475.

    PMID: 39349993
  8. 8

    Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial).

    Hyun J, Lee SA, Lee SE, et al.

    Korean circulation journal 2025; (55(12)):1077-1089 doi:10.4070/kcj.2025.0052.

    PMID: 40736394
  9. 9

    Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies.

    Kodur N, Tang WHW

    JACC. Heart failure 2025; (13(4)):537-553 doi:10.1016/j.jchf.2025.02.007.

    PMID: 40204384
  10. 10

    Universal Definition and Classification of Heart Failure.

    Bozkurt B, Coats A, Tsutsui H

    Journal of cardiac failure 2021; doi:10.1016/j.cardfail.2021.01.022.

    PMID: 33662581
  11. 11

    An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.

    Araújo CS, Marco I, Restrepo-Córdoba MA, et al.

    Journal of clinical medicine 2024; (13(23)) doi:10.3390/jcm13237171.

    PMID: 39685630

This page is for informational purposes only and does not constitute medical advice. Your clinician should interpret your ejection fraction, heart failure stage, and NYHA class and guide any medication changes.

Get notified when new evidence is published on congestive heart failure.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.